NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT07416682 2026-02-25
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06698744 2025-09-23
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT06986434 2025-09-03
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07085728 2025-08-22
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT06472479 2024-06-28
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Not yet recruiting
NCT05909826 2023-06-18
KMM-KCd
Dong-A University Hospital
Phase 2 Not yet recruiting